Immunic (IMUX) EBITDA (2013 - 2026)

Immunic has disclosed EBITDA across 14 years of filings, most recently posting -$32.2 million for Q1 2026.

• EBITDA for Q1 2026 came in at -$32.2 million, down 24.93% year-over-year; the trailing twelve-month figure through Mar 2026 was -$105.2 million (down 8.68% YoY), and the FY2025 annual result was -$98.7 million, up 1.32% from the prior year.
• EBITDA came in at -$32.2 million for Q1 2026 at Immunic, down from -$19.2 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$19.2 million in Q4 2025 to a low of -$53.1 million in Q4 2022.
• The 5-year median for EBITDA is -$24.3 million (2024), against an average of -$25.9 million.
• Across the five-year window, EBITDA tumbled 157.08% in 2022 and jumped 59.06% in 2023, its largest moves.
• Immunic's EBITDA stood at -$53.1 million in 2022, then soared by 59.06% to -$21.7 million in 2023, then declined by 14.43% to -$24.9 million in 2024, then grew by 22.61% to -$19.2 million in 2025, then plunged by 67.3% to -$32.2 million in 2026.
• The last three EBITDA figures came in at -$32.2 million (Q1 2026), -$19.2 million (Q4 2025), and -$25.5 million (Q3 2025), per Business Quant data.